These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11103926)

  • 61. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
    Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
    Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Economic evaluation and the postponement of health care costs.
    van Baal PH; Feenstra TL; Polder JJ; Hoogenveen RT; Brouwer WB
    Health Econ; 2011 Apr; 20(4):432-45. PubMed ID: 21210494
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Stents in peripheral arterial occlusive diseases (PAOD)].
    Roeren T
    Ther Umsch; 2003 Apr; 60(4):199-203. PubMed ID: 12731429
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section.
    Cooper NJ; Sutton AJ; Abrams KR
    Stat Methods Med Res; 2002 Dec; 11(6):491-512. PubMed ID: 12516986
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Costs of stenting for acute myocardial infarction.
    van 't Hof AW; Suryapranata H; de Boer MJ; Hoorntje JC; Zijlstra F
    Lancet; 1998 Jun; 351(9118):1817. PubMed ID: 9635984
    [No Abstract]   [Full Text] [Related]  

  • 66. Iliac arterial occlusive disease: cost-effectiveness analysis of stent placement versus percutaneous transluminal angioplasty. Dutch Iliac Stent Trial Study Group.
    Bosch JL; Tetteroo E; Mali WP; Hunink MG
    Radiology; 1998 Sep; 208(3):641-8. PubMed ID: 9722840
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.
    Willan AR; O'Brien BJ
    Health Econ; 1999 May; 8(3):203-11. PubMed ID: 10348415
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials.
    De Luca G; Suryapranata H; Stone GW; Antoniucci D; Biondi-Zoccai G; Kastrati A; Chiariello M; Marino P
    Int J Cardiol; 2008 May; 126(1):37-44. PubMed ID: 17544528
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of an aggressive stenting strategy on initial and one-year follow-up costs in patients undergoing coronary angioplasty.
    Farshid A; Leong B; Pitney M; McCredie RM; Allan R
    Aust N Z J Med; 1999 Apr; 29(2):243-8. PubMed ID: 10342025
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bayesian methods in health technology assessment: a review.
    Spiegelhalter DJ; Myles JP; Jones DR; Abrams KR
    Health Technol Assess; 2000; 4(38):1-130. PubMed ID: 11134920
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Intracoronary prosthesis (stent): an approach to the analysis of cost-effectiveness].
    Iñíguez Romo A
    Rev Esp Cardiol; 1997; 50 Suppl 2():83-94. PubMed ID: 9221460
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both?
    Oh PI; Cohen EA; Mittmann N; Seung SJ
    Can J Clin Pharmacol; 2004; 11(2):e202-11. PubMed ID: 15520474
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A one-year comparison of cost and outcomes of angioplasty in stent and nonstent patients.
    Sen SS; Khandker RK; Roth DA; Thomas J
    Am J Ther; 2005; 12(3):210-7. PubMed ID: 15891263
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Iliac occlusions: stenting or crossover grafting? An examination of patency and cost.
    Whatling PJ; Gibson M; Torrie EP; Magee TR; Galland RB
    Eur J Vasc Endovasc Surg; 2000 Jul; 20(1):36-40. PubMed ID: 10906295
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bayesian modelling of healthcare resource use in multinational randomized clinical trials.
    Gauthier A; Manca A; Anton S
    Pharmacoeconomics; 2009; 27(12):1017-29. PubMed ID: 19908926
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction.
    Jackson CH; Sharples LD; Thompson SG
    Int J Biostat; 2010; 6(1):Article 34. PubMed ID: 21969987
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bayesian and classical estimation of mixed logit: An application to genetic testing.
    Regier DA; Ryan M; Phimister E; Marra CA
    J Health Econ; 2009 May; 28(3):598-610. PubMed ID: 19345433
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The importance of the comparator in economic evaluations: working on the efficiency frontier.
    Neyt M; Van Brabandt H
    Pharmacoeconomics; 2011 Nov; 29(11):913-6. PubMed ID: 21988290
    [No Abstract]   [Full Text] [Related]  

  • 80. A scoping review of statistical methods for trial-based economic evaluations: The current state of play.
    El Alili M; van Dongen JM; Esser JL; Heymans MW; van Tulder MW; Bosmans JE
    Health Econ; 2022 Dec; 31(12):2680-2699. PubMed ID: 36089775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.